Clinical trialsCompany release

Sagimet doses first US Phase 3 acne patient with denifanstat, extends cash runway to mid-2029

🇺🇸 Sagimet Biosciences Inc. (SGMT) · Thu 12 Nov 2026

The US biotech reports first dosing in its AURORA trial, with topline data due in the second half of 2027, after a $115M October financing.

Sagimet Biosciences said in a November 2026 corporate presentation that the first patient was dosed in October 2026 in AURORA, its US Phase 3 trial of denifanstat in moderate to severe acne. The company expects topline data in the second half of 2027.

Sagimet also reported pro forma cash of about $356M following a $115M financing completed in October. It expects this to fund operations until mid-2029, a horizon that would extend beyond the expected AURORA readout.

The presentation also noted that Ascletis, Sagimet's partner for denifanstat, had its new drug application for the acne indication accepted by China's National Medical Products Administration (NMPA) in December 2025. The material provided does not give a decision timeline for that filing.

Sagimet expects to start a Phase 2 trial of TVB-3567, a follow-on fatty acid synthase (FASN) inhibitor, in acne by the end of 2026. Further development in metabolic dysfunction-associated steatohepatitis (MASH) is contingent on securing non-dilutive funding, the company said.

What it means for your team

  • The AURORA readout in 2H 2027 is the next key clinical milestone for denifanstat in acne; a US filing would depend on those results.
  • A China NDA acceptance for denifanstat in acne marks the first regulatory filing for the drug in this indication, handled by partner Ascletis.
  • Funding to mid-2029 gives Sagimet runway through the Phase 3 readout, while MASH work depends on non-dilutive funding.
  • Teams tracking FASN inhibitors should note the planned TVB-3567 Phase 2 start in acne by end-2026.

Company's press release (SEC filing): Sagimet Biosciences Inc. ↗

Article written by VigiEye from the official source (Sagimet Biosciences Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →